IP Group - visionary ventures

📊 2025 results out 📈 NAV per share up 13% to 110.4p; 💡 Opportunity for significant potential future royalty income as Group benefits from financial exposure to Pfizer’s obesity drug franchise; 💷 Confirmed target of delivering more than £250m of exits between 2025 and the end of 2027, having raised £68m in the year from exits. bit.ly/4bs832d #visionaryventures

$IPO Here's why IP Group looks undervalued. Three brokers take a deep dive tinyurl.com/2d555hy5 @IPGroupplc #IPO

Couldn't make today's live presentation with IP GROUP PLC? #IPO @IPGroupplc No problem! Catch up here: youtube.com/watch?v=f3T3tQ…

IP Group CEO on 2025 highlights, NAV uplift, Pfizer royalties & capital allocation @IPGroupplc proactiveinvestors.com/companies/news… #IPGroup #IPGroupPLC #GregSmith #LSEIPO #Pfizer #BiotechInvesting #VentureCapital #UKTech #HingeHealth #Oxa #Artios #HealthcareInnovation #GrowthInvesting #StockMarketUK #IPO

🌱⚡ IP Group Australia is thrilled to have invested in MGA Thermal, a clean energy company developing long‑duration thermal energy storage that enables renewable power to deliver industrial‑grade heat, 24/7. Shane Meaney of IP Group Australia will join MGA Thermal’s Board. Read more: bit.ly/3PCVxFS

📬 Our March newsletter is now live ,ft. the latest news from across the Group & our portfolio, inc. Oxa, @MicrobioticaLtd & @AccelerComm. 👉 Read the newsletter: bit.ly/3Ni8gwT ✉️ Sign up to receive future editions: bit.ly/4s0MsFd

🚀🌍 An exciting update from portfolio company @AccelerComm, which has announced it has expanded its satellite 5G partnership with @Radisys. 🔗 Read more: bit.ly/4l4B1JX

🚀 Huge congratulations to portfolio company Oxa on the successful first close of its Series D funding round, raising $103m 🎉 This investment will enable Oxa to accelerate the commercialisation of its Industrial Mobility Automation (IMA) solutions, automating repetitive industrial driving tasks and unlocking new efficiencies across sectors. 🔗Read more: bit.ly/4crdUr0

⚡ Great news from IP Group Australia portfolio company Banksia Minerals Processing, which has secured a Federal Government grant of up to A$5 million from @arenagovau through its Advancing Renewables Program (ARP). 🔗 Read more: bit.ly/40amOld

Congratulations to portfolio company @artiospharma on receiving its second U.S. FDA Fast Track Designation. 🧬 Read more: bit.ly/4s2S3uk

Great to see portfolio company @OXCCU_Tech receiving national attention for its progress in scaling sustainable aviation fuel (SAF) technology. Proud to support this journey through IP Group — and excited to see what comes next. Read more here⬇️ thetimes.com/article/f63d0e…

Great to see portfolio company @MicrobioticaLtd report highly encouraging Phase 1b results for MB310, its precision microbiome therapy for ulcerative colitis. More here: bit.ly/4r7ri7V

Celebrating #InternationalDayofWomenandGirlsinScience 👩‍🔬✨ Last year, @IPGroupplc, together with our EIS fund management business @ParkwalkAdvisor, sponsored 4 placements on the @form_future Cambridge Unlocked programme. Our aim was to help broaden access to #STEM careers for talented young women by providing meaningful exposure to real scientific and technical environments. The programme helped build confidence, skills and a clear sense of what’s possible in STEM careers. Here’s to empowering the next generation of scientists, engineers and innovators.👧‍🔬🧬 #WomenInScience

Today, on #WorldCancerDay, we’d like to shine a light on our portfolio companies working to research, treat and fight cancer. 🩺 We are proud to support a range of innovative clinical-stage companies spanning various modalities, which are all developing first-in-class and/or best-in-class therapies to stop cancer: 🧬Artios: Pioneering breakthroughs and innovations in DNA Damage Response (DDR) based treatments to address a broad spectrum of difficult-to-treat cancers. 🧬Iksuda Therapeutics: advancing a differentiated pipeline of antibody drug conjugates (ADCs) for hard-to-treat cancers. 🧬Microbiotica: Translating clinic-led microbiome science into transformative life-changing medicines. 🧬STORM Therapeutics: Discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RME). Throughout 2025, these companies enrolled patients into clinical trials, and we look forward to following their progress as those studies develop. #WorldCancerDay

CEO Greg Smith will be taking part in the @UKPrivateCap Conferences & Receptions across the Middle East next week. He will be speaking in Abu Dhabi (3rd February) and Dubai (5th February) to discuss the European private capital landscape and the opportunities and strategies that will deliver. #EuropeanPrivateCapital

✨ Great to see portfolio companies Autifony Therapeutics, Genomics and LIO recognised in the hardware category of the Sunday Times 100 Tech as some of Britain’s fastest-growing private technology companies. 📰Read the full list in The Times: lnkd.in/dCyAjxMn

Congratulations to DeepTech portfolio company @AccelerComm which is now an Airbus UpNext SpaceRAN demonstrator partner. This marks a significant milestone for the company, whose high‑performance, space‑proven 5G physical layer technology is now helping to enable the next generation of LEO satellite communication networks. A major achievement for the team as they continue driving innovation in satellite‑enabled 5G.

Take a look at our EIS fund management business Parkwalk’s sleek new website. 🎉 A great milestone as the team continues to back ground-breaking DeepTech, HealthTech and CleanTech university spinouts.

Looking back at 2025: A Year of Impact and Innovation 🚀 From @HingeHealth's IPO on the @NYSE, to major fundraises by @artiospharma, @OXCCU_Tech, @AccelerComm & Rage Biotech, to strategic exits like @Monolith_AI’s sale to @CoreWeave, our portfolio has continued to shape the future across healthtech, deeptech and cleantech. The year also brought exciting progress towards potential future royalty income from @MetseraInc obesity drug candidates Together with our EIS fund management business @ParkwalkAdvisor, we’re proud to be the most active investor in UK spinouts, driving progress for a healthier, tech-enriched, and sustainable future. We look forward to what 2026 has in store!

🎄✨ All of us at IP Group wish you and yours a safe and happy festive season and New Year! Thank you for all of your support in 2025. We’ve celebrated some key milestones within the portfolio this year and look forward to what 2026 brings. 🎉